Calliditas Therapeutics' Shares Gain Following Conditional Marketing Authorization From European Commission For Kidney Disease Candidate
The European Commission (EC) has granted conditional marketing authorization for Calliditas Therapeutics’s (NASDAQ: CALT) Kinpeygo for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN).
